Healthy
Conditions
Brief summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Interventions
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
24 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2
Exclusion criteria
The main
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the AUC0-inf of rosuvastatin. |
| Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the AUC0-inf of furosemide. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Experience an Adverse Event (AE) | Up to approximately 1 month | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. |
| Number of Participants Who Discontinue Study Treatment Due to an AE | Up to approximately 2 weeks | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in who discontinue study treatment due to an AE will be reported. |
| Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the AUC0-last of rosuvastatin. |
| Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the AUC0-last of furosemide. |
| Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin | At designated time points (up to approximately 24 hours) | Blood samples will be collected to determine the AUC0-24 of rosuvastatin. |
| Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Furosemide | At designated time points (up to approximately 24 hours) | Blood samples will be collected to determine the AUC0-24 of furosemide. |
| Maximum Plasma Concentration (Cmax) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Cmax of rosuvastatin. |
| Maximum Plasma Concentration (Cmax) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Cmax of furosemide. |
| Time of the Maximum Plasma Concentration (Tmax) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Tmax of rosuvastatin. |
| Time of the Maximum Plasma Concentration (Tmax) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Tmax of furosemide. |
| Terminal Half-life (t1/2) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the t1/2 of rosuvastatin. |
| Terminal Half-life (t1/2) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the t1/2 of furosemide. |
| Apparent Total Plasma Clearance (CL/F) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the CL/F of rosuvastatin. |
| Apparent Total Plasma Clearance (CL/F) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the CL/F of furosemide. |
| Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Rosuvastatin | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Vz/F of rosuvastatin. |
| Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Furosemide | At designated time points (up to approximately 2 weeks) | Blood samples will be collected to determine the Vz/F of furosemide. |
Countries
United States
Contacts
STUDY_DIRECTORMedical Director
Merck Sharp & Dohme LLC
Outcome results
None listed